Skip to main content

and
  1. No Access

    Article

    Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

    This study was performed in order to evaluate the toxicities, progression-free and overall survival of patients with responsive residual or recurrent ovarian cancer treated with high-dose chemotherapy. Twenty-...

    RJ Morgan, JH Doroshow, L Leong, J Schriber, S Shibata in Bone Marrow Transplantation (2001)